Top Story

Second part of phase 2 glaucoma study approved in Bulgaria

December 17, 2014

Regulatory authorities in Bulgaria approved patient enrollment for the second cohort of a phase 2 clinical study in glaucoma, Can-Fite BioPharma and OphthaliX announced in a press release.

In the first cohort study, patients were treated with 1 mg CF101, an A3 adenosine receptor agonist that acts as a neuroprotective agent and prevents apoptosis of retinal ganglion cells, or placebo. Masked results showed that CF101 had a favorable safety profile and was well-tolerated, the release said. A previous ophthalmic study showed CF101 lowered IOP.

In the Journals

Next-generation DNA sequencing may have capability to detect congenital cataracts

December 17, 2014
Next-generation DNA sequencing demonstrated the capability to alter clinical management, direct care pathways and enable accurate genetic counseling in the diagnosis of…
thumbnail for video 3932502583001 Meeting News CoverageVideo

VIDEO: Controversies in pterygium surgery

December 17, 2014
NEW YORK — At OSN New York, William B. Trattler, MD, dispels misconceptions about pterygium surgery.
Publication Exclusive

How aligned are your partners and staff?

December 17, 2014
“Align: verb; to arrange things so that they form a line or are in a proper position; to change (something) so that it agrees with or matches something…

Actavis’ newly appointed senior management team effective after Allergan acquisition

December 16, 2014
Actavis announced that the company’s newly appointed management team will become effective immediately after the anticipated successful close of the Allergan…
More News Headlines »
Short Subjects

Choroidal Melanoma in Children: Be Aware of Risks

Journal of Pediatric Ophthalmology and Strabismus, Volume -2147483648
Online Only, December 12, 2014
The authors describe a case of choroidal melanoma in a 13-year-old girl treated with plaque brachytherapy. Uveal…
More »

Diabetic Eye Disease: Implications of Early Recognition, Treatment, and Continuity of Care

This activity is supported by an educational grant from Genentech, Inc.

Diabetic retinopathy is a leading cause of new cases of legal blindness among working-age Americans. Initially…
More »
Meeting News Coverage Video
thumbnail for video 3932482435001

Treating residual astigmatism after toric IOL

December 16, 2014
NEW YORK — At OSN New York, John P. Berdahl, MD, discusses how he treats patients with residual astigmatism caused by…
More »